Physicians, health insurers and patients now want to know how well a drug will work and affect total medical costs. Yet, health plan leaders find the information currently provided by the biopharmaceutical industry no longer suffices. As the basis for payment shifts to improved patient outcomes, health organizations are looking for more robust evidence of clinical and economic comparative effectiveness. Drug makers that have faced challenges with formulary acceptance or reimbursement levels will need to speed their efforts to create and reliably demonstrate better outcomes for patients. Pharmaceutical companies that are first to meet healthcare’s new expectations of value could have an advantage in the competition for market share and brand differentiation.
In this session, the changing payment landscape for the US pharmaceutical industry is examined, with a look at how health insurers view evidence of drug effectiveness, contracting strategies and relationships with pharmaceutical companies. Five major forces dramatically altering pharmaceutical revenue models are examined, including: (1) pharma's big bet on biologics; (2) the movement toward outcomes-based payments; (3) the demand for more and better data; (4) patient compliance; and (5) technology and increased transparency.
Please join PwC's Christopher Khoury on Thursday, August 9th, 2012 as he presents PwC research findings and explores potential paths for drug manufacturers to unleash value, improve clinical and economic evidence of comparative effectiveness, and build trust with other health organizations.
- Understand the five forces dramatically altering pharmaceutical revenue models
- Consider health plan perspectives on evidence of drug effectiveness, contracting strategies and relationships with pharmaceutical companies
- Explore the implications for pharmaceutical companies, health plans, PBMs, and other applicable stakeholders regarding PwC research findings
- Examine how pharmaceutical organization and health plan relationships will evolve, and how stakeholders should position themselves for future success in this arena
- Engage in interactive learning through online question submission, attendee feedback and opportunity for follow up questions, and networking with attendees, faculty and other professionals through dedicated LinkedIn group
Interested attendees would include:
- C-Suite Executives
- Prescription Benefit Executives and Staff
- Pharmaceutical Managed Market Executives and Staff
- Medical Directors
- Pharmacy Directors
- Comparative Effectiveness Executives and Staff
- Contracting Executives and Staff
- Strategy and Planning Executives and Staff
- Business Intelligence Staff
- Other Interested Parties
Attendees would represent organizations including:
- Pharmaceutical Organizations
- Health Plans
- PBMs
- Employers
- Third Party Administrators
- Benefit Consulting Organizations
- Provider Networks and Accountable Care Organizations
- Hospitals and Health Systems
- Solutions Providers
- Associations, Institutes and Research Organizations
- Media
- Other Interested Organizations
| Individual Registration Fee: $195. Audio Conference CD-ROM: $40 for attendees; $285 for non-attendees after the event. | |||||
|
Christopher Khoury, MSc, MBA Senior Manager, Health Research Institute, PwC |
Christopher Khoury is a Senior Manager of the Health Research Institute (HRI). HRI is a dedicated research group that provides new intelligence, perspective, and analysis on major health-related business issues. Christopher's primary focus is pharmaceutical, life sciences and biotechnology thought leadership and research initiatives. He has worked in the healthcare sector for 12 years. Prior to joining HRI, he advised clients on workplace, customer, and brand strategy issues in provider, philanthropy and government health sectors. He previously worked in life sciences R&D, product development, and as a data manager at an academic medical center. Christopher is the author of several publications and spoken presentations on health, technology, and management subject matter. He also holds patents covering biotechnology subjects. Christopher earned an M.B.A. from The Ohio State University Fisher College of Business magna cum laude. Christopher received his B.S. from the University of Illinois and holds an M.S. in biomedical engineering from the University of Wisconsin. |
|
 |
|